A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (NCT06840392)
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Who can join: Review the eligibility criteria below.
Location: Total Skin and Beauty Dermatology Center PC — Birmingham, Alabama
Age range: 12 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (130 Sites)
Showing the first 25 of 130 sites.
- Total Skin and Beauty Dermatology Center PC — Birmingham, Alabama
- CTT Research — Gilbert, Arizona
- Ctr for Dermatology Clinical Res — Fremont, California
- USC Keck School of Medicine — Los Angeles, California
- MedDerm Associates — San Diego, California
- Driven Research — Miami, Florida
- Floridian Research Institute — Miami, Florida
- Sarasota Arthritis Res Ctr — Sarasota, Florida
- University Of South Florida — Tampa, Florida
- Emory School of Med Dermatology — Atlanta, Georgia
- Atlanta Biomedical Clin Res LLC — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Endeavor Health — Glenview, Illinois
- Dundee Dermatology — West Dundee, Illinois
- Southern IN Clinical Trials — New Albany, Indiana
- Beth Israel Deaconess Med Center — Boston, Massachusetts
- Metro Boston Clinical Partners — Brighton, Massachusetts
- Clinical Research Inst of MI — Chesterfield, Michigan
- Deluxe Dermatology — St Louis, Missouri
- Skin Specialists PC — Omaha, Nebraska
- Vivida Dermatology — Las Vegas, Nevada
- North Shore University Hospital — New Hyde Park, New York
- Cameron Dermatology — New York, New York
- Optima Research Boardman — Boardman, Ohio
- Ohio State University — Columbus, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hidradenitis Suppurativa
- A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) — Phoenix, Arizona
- Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa — Boston, Massachusetts
- A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) — Birmingham, Alabama
Explore by condition: All Hidradenitis Suppurativa clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.